{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T13:32:25Z","timestamp":1772803945491,"version":"3.50.1"},"reference-count":60,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Universit\u00e0 Cattolica del Sacro Cuore Fondazione Policlinico Universitario \u201cA. Gemelli\u201d IRCCS"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>The antibody-related immune response is mediated by immunoglobulins (Igs), soluble circulating glycoproteins produced by activated B cells that, upon the recognition of specific epitopes on pathogen surfaces, activate, proliferate, and differentiate into antibody-secreting plasma cells. Although the antibodies are effectors of the humoral immune adaptive response, their overproduction in response to a dysregulated proliferation of clonal plasma cell production in tumoral conditions (i.e., multiple myeloma), enriches the serum and urinary matrices, assuming the crucial role of biomarkers. Multiple myeloma (MM) is a plasma cell dyscrasia characterized by the expansion and accumulation of clonally activated plasma cells in bone marrow, determining the release of high amounts of monoclonal component (MC) that can be detected as intact immunoglobulin (Ig), immunoglobulin fragments, or free light chains (FLCs). The importance of detecting biomarkers for the diagnosis, monitoring, and prognosis of diseases is highlighted by the international guidelines that recommend specific assays for the analysis of intact Igs and FLC. Moreover, a developed assay called Hevylite\u00ae allows for the quantification of immunoglobulins that are both involved (iHLC) and not involved (uHLC) in the tumor process; this is a fundamental aspect of following up the patient\u2019s workup and evaluating the progression of disease, together with the treatments response. We here summarize the major points of the complex scenario involving monoclonal gammopathies and MM clinical management in view of advantages derived for the use of Hevylite\u00ae.<\/jats:p>","DOI":"10.3390\/jpm13050743","type":"journal-article","created":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T02:50:00Z","timestamp":1682563800000},"page":"743","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Laboratory and Clinical Settings of Heavy\/Light Chain (HLC) Assays in the Management of Monoclonal Gammopathies and Multiple Myeloma"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8720-6284","authenticated-orcid":false,"given":"Cecilia","family":"Napodano","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, S. Agostino Estense Hospital, 41126 Modena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Ioannilli","sequence":"additional","affiliation":[{"name":"Scientific Department, The Binding Site Italy, Part of Thermo Fisher Scientific, 24050 Bergamo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerio","family":"Basile","sequence":"additional","affiliation":[{"name":"Clinical Pathology Unit and Cancer Biobank, Department of Research and Advanced Technologies, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Gulli","sequence":"additional","affiliation":[{"name":"Clinical Biochemistry Laboratory, IRCCS \u201cBambino Ges\u00f9\u201d Children\u2019s Hospital, 00165 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Carnazzo","sequence":"additional","affiliation":[{"name":"Department of Clinical Pathology, Santa Maria Goretti Hospital, AUSL Latina, 04100 Latina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Pignalosa","sequence":"additional","affiliation":[{"name":"Department of Clinical Pathology, Santa Maria Goretti Hospital, AUSL Latina, 04100 Latina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Di Biase","sequence":"additional","affiliation":[{"name":"Department of Clinical Pathology, Santa Maria Goretti Hospital, AUSL Latina, 04100 Latina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica","family":"Cavaleri","sequence":"additional","affiliation":[{"name":"Department of Clinical Pathology, Santa Maria Goretti Hospital, AUSL Latina, 04100 Latina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cosimo","family":"Racco","sequence":"additional","affiliation":[{"name":"Department of Clinical Pathology, Santa Maria Goretti Hospital, AUSL Latina, 04100 Latina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5400-4996","authenticated-orcid":false,"given":"Francesco","family":"Equitani","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine and Immuno-Hematology, Santa Maria Goretti Hospital, AUSL Latina, 04100 Latina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9155-6378","authenticated-orcid":false,"given":"Mariapaola","family":"Marino","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicina e Chirurgia Traslazionale, Sezione di Patologia Generale, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"},{"name":"Fondazione Policlinico Universitario \u201cA. Gemelli\u201d IRCCS, 00168 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8328-2570","authenticated-orcid":false,"given":"Umberto","family":"Basile","sequence":"additional","affiliation":[{"name":"Department of Clinical Pathology, Santa Maria Goretti Hospital, AUSL Latina, 04100 Latina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"International Myeloma Working Group (2003). Criteria for the Classification of Monoclonal Gammopathies, Multiple Myeloma and Related Disorders: A Report of the International Myeloma Working Group. Br. J. Haematol., 121, 749\u2013757.","DOI":"10.1046\/j.1365-2141.2003.04355.x"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/clinchem\/47.4.673","article-title":"Highly Sensitive, Automated Immunoassay for Immunoglobulin Free Light Chains in Serum and Urine","volume":"47","author":"Bradwell","year":"2001","journal-title":"Clin. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1586\/14737159.2014.864557","article-title":"Serum Free Light Chain Analysis in the Diagnosis and Management of Multiple Myeloma and Related Conditions","volume":"14","author":"Graziani","year":"2014","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/bjh.14196","article-title":"Recommendations for the Diagnosis and Initial Evaluation of Patients with Waldenstr\u00f6m Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenstr\u00f6m Macroglobulinaemia","volume":"175","author":"Castillo","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e306","DOI":"10.1038\/bcj.2015.32","article-title":"The Cellular Immune System in Myelomagenesis: NK Cells and T Cells in the Development of Myeloma [corrected] and Their Uses in Immunotherapies","volume":"5","author":"Dosani","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"827","DOI":"10.4149\/neo_2015_100","article-title":"Immunoparesis in MGUS\u2014Relationship of Uninvolved Immunoglobulin Pair Suppression and Polyclonal Immunoglobuline Levels to MGUS Risk Categories","volume":"62","author":"Pika","year":"2015","journal-title":"Neoplasma"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"R\u00edos-Tamayo, R., Puig, N., Algar\u00edn, M., Garc\u00eda de Veas Silva, J.L., Barbosa, N., Encinas, C., Hern\u00e1ndez, J.\u00c1., Alonso, R., Campos, M.L., and Rodr\u00edguez, T. (2021). The Current Role of the Heavy\/Light Chain Assay in the Diagnosis, Prognosis and Monitoring of Multiple Myeloma: An Evidence-Based Approach. Diagnostics, 11.","DOI":"10.3390\/diagnostics11112020"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1182\/blood-2018-04-839480","article-title":"Monoclonal Gammopathy of Clinical Significance: A Novel Concept with Therapeutic Implications","volume":"132","author":"Fermand","year":"2018","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1182\/bloodadvances.2019031914","article-title":"Pathophysiology and Management of Monoclonal Gammopathy of Renal Significance","volume":"3","author":"Jain","year":"2019","journal-title":"Blood Adv."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1182\/blood-2006-03-001164","article-title":"Dangerous Small B-Cell Clones","volume":"108","author":"Merlini","year":"2006","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41581-018-0102-7","article-title":"Publisher Correction: The Evaluation of Monoclonal Gammopathy of Renal Significance: A Consensus Report of the International Kidney and Monoclonal Gammopathy Research Group","volume":"15","author":"Leung","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/ki.2014.408","article-title":"Diagnosis of Monoclonal Gammopathy of Renal Significance","volume":"87","author":"Bridoux","year":"2015","journal-title":"Kidney Int."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2008.291","article-title":"Criteria for Diagnosis, Staging, Risk Stratification and Response Assessment of Multiple Myeloma","volume":"23","author":"Kyle","year":"2009","journal-title":"Leukemia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S1470-2045(16)30124-3","article-title":"Lenalidomide plus Dexamethasone versus Observation in Patients with High-Risk Smouldering Multiple Myeloma (QuiRedex): Long-Term Follow-up of a Randomised, Controlled, Phase 3 Trial","volume":"17","author":"Mateos","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/qjmed\/hcm077","article-title":"Multiple Myeloma: Causes and Consequences of Delay in Diagnosis","volume":"100","author":"Kariyawasan","year":"2007","journal-title":"QJM"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1365-2141.2009.07952.x","article-title":"Frequency of Altered Monoclonal Protein Production at Relapse of Multiple Myeloma","volume":"148","author":"Hobbs","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1172\/JCI61188","article-title":"Molecular Pathogenesis of Multiple Myeloma and Its Premalignant Precursor","volume":"122","author":"Kuehl","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_21","first-page":"232546","article-title":"Implications of Heterogeneity in Multiple Myeloma","volume":"2014","author":"Lim","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1182\/blood-2006-02-005496","article-title":"Integration of Global SNP-Based Mapping and Expression Arrays Reveals Key Regions, Mechanisms, and Genes Important in the Pathogenesis of Multiple Myeloma","volume":"108","author":"Walker","year":"2006","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1182\/blood-2013-12-542662","article-title":"Serum Free Immunoglobulin Light Chain Evaluation as a Marker of Impact from Intraclonal Heterogeneity on Myeloma Outcome","volume":"123","author":"Brioli","year":"2014","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1182\/blood-2011-01-332320","article-title":"Long-Term Prognostic Significance of Response in Multiple Myeloma after Stem Cell Transplantation","volume":"118","author":"Blade","year":"2011","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.trsl.2018.05.003","article-title":"Novel Biomarkers in Multiple Myeloma","volume":"201","author":"Levin","year":"2018","journal-title":"Transl. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/2162-3619-1-9","article-title":"Ratio of Involved\/uninvolved Immunoglobulin Quantification by HevyliteTM Assay: Clinical and Prognostic Impact in Multiple Myeloma","volume":"1","author":"Koulieris","year":"2012","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1373\/clinchem.2009.123828","article-title":"Assessment of Monoclonal Gammopathies by Nephelometric Measurement of Individual Immunoglobulin Kappa\/lambda Ratios","volume":"55","author":"Bradwell","year":"2009","journal-title":"Clin. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.pathol.2019.04.002","article-title":"Heavy\/light Chain Assay in the Monitoring of Multiple Myeloma","volume":"51","author":"Ting","year":"2019","journal-title":"Pathology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/ajh.24402","article-title":"Multiple Myeloma: 2016 Update on Diagnosis, Risk-Stratification, and Management","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.3109\/10428194.2013.767456","article-title":"Immunoglobulin Heavy Chain\/light Chain Pair Measurement Is Associated with Survival in Diffuse Large B-Cell Lymphoma","volume":"54","author":"Jardin","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/leu.2012.159","article-title":"Prognostic Utility of Intact Immunoglobulin Ig\u2032\u03ba\/Ig\u2032\u03bb Ratios in Multiple Myeloma Patients","volume":"27","author":"Bradwell","year":"2013","journal-title":"Leukemia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group Consensus Criteria for Response and Minimal Residual Disease Assessment in Multiple Myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ajh.24268","article-title":"Suppression of the Noninvolved Pair of the Myeloma Isotype Correlates with Poor Survival in Newly Diagnosed and Relapsed\/refractory Patients with Myeloma","volume":"91","author":"Ludwig","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/bjh.12679","article-title":"Involved\/uninvolved Immunoglobulin Ratio Identifies Monoclonal Gammopathy of Undetermined Significance Patients at High Risk of Progression to Multiple Myeloma","volume":"164","author":"Medina","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/leu.2012.197","article-title":"Immunoglobulin Heavy\/light Chain Ratios Improve Paraprotein Detection and Monitoring, Identify Residual Disease and Correlate with Survival in Multiple Myeloma Patients","volume":"27","author":"Ludwig","year":"2013","journal-title":"Leukemia"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/0004563214564225","article-title":"Comparison of HevyliteTM IgA and IgG Assay with Conventional Techniques for the Diagnosis and Follow-up of Plasma Cell Dyscrasia","volume":"52","author":"Paolini","year":"2015","journal-title":"Ann. Clin. Biochem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2010-10-299529","article-title":"Consensus Recommendations for Standard Investigative Workup: Report of the International Myeloma Workshop Consensus Panel 3","volume":"117","author":"Dimopoulos","year":"2011","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1373\/clinchem.2014.234757","article-title":"Heavy\/light Chain Assay for Monitoring IgA Multiple Myeloma: Digging out the IgA from the \u03b2 Region","volume":"61","author":"Calderon","year":"2015","journal-title":"Clin. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1182\/blood.V120.21.3970.3970","article-title":"IgA Hevylite\u00ae Test as a Surrogate to Serum Protein Electrophoresis (SPEP) or Nephelometry in the Management of IgA Myeloma","volume":"120","author":"Boyle","year":"2012","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1182\/blood.V114.22.1818.1818","article-title":"Heavy\/Light Chain Specific Immunoglobulin Ratios at Presentation Are Prognostic for Progression Free Survival in the IFM 2005-01 Myeloma Trial","volume":"114","author":"AvetLoiseau","year":"2009","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1111\/ijlh.12050","article-title":"Evaluation of the Heavy\/light-Chain Assay for the Diagnosis and Monitoring of Multiple Myeloma","volume":"35","author":"Chae","year":"2013","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1373\/clinchem.2014.231985","article-title":"Monitoring IgA Multiple Myeloma: Immunoglobulin Heavy\/light Chain Assays","volume":"61","author":"Katzmann","year":"2015","journal-title":"Clin. Chem."},{"key":"ref_43","unstructured":"Michallet, M., Chapuis-Cellier, C., Lombard, C., Sobh, M., Dejoie, T., Caillon, H., Attal, M., Moreau, P., and Avet-Loiseau, H. (2023, March 02). Novel Therapies Differentially Impact Polyclonal Immunoglobulin Recovery in Myeloma Patients: A Longitudinal Study. Available online: https:\/\/library.ehaweb.org\/eha\/2018\/stockholm\/215612\/mauricette.michallet.novel.therapies.differentially.impact.polyclonal.html."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"599532","DOI":"10.3389\/fonc.2021.599532","article-title":"HLC Pair Suppression as a Risk Factor for Bacterial Bloodstream Infections and Early Mortality in Newly Diagnosed Intact Immunoglobulin Multiple Myeloma Patients","volume":"11","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/bjh.14026","article-title":"Levels of Uninvolved Immunoglobulins Predict Clinical Status and Progression-Free Survival for Multiple Myeloma Patients","volume":"174","author":"Harutyunyan","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/leu.2017.209","article-title":"Heavy Light Chain Monitoring Correlates with Clinical Outcome in Multiple Myeloma Patients","volume":"32","author":"Michallet","year":"2018","journal-title":"Leukemia"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1515\/cclm-2015-0692","article-title":"Quantification of \u03b2 Region IgA Paraproteins\u2014Should We Include Immunochemical \u201cHeavy\/light Chain\u201d Measurements? Counterpoint","volume":"54","author":"Paolini","year":"2016","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1515\/cclm-2017-0817","article-title":"Analytical Validation of the Hevylite Assays for M-Protein Quantification","volume":"56","author":"Jacobs","year":"2018","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.3892\/ol.2016.4965","article-title":"Combined Use of Free Light Chain and Heavy\/light Chain Ratios Allow Diagnosis and Monitoring of Patients with Monoclonal Gammopathies: Experience of a Single Institute, with Three Exemplar Case Reports","volume":"12","author":"Gagliardi","year":"2016","journal-title":"Oncol. Lett."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.cca.2018.01.010","article-title":"Heavy\/light Chain Assay as a Biomarker for Diagnosis and Follow-up of Multiple Myeloma","volume":"479","author":"Chae","year":"2018","journal-title":"Clin. Chim. Acta"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1080\/10428194.2017.1339876","article-title":"Heavy + Light Chain Analysis to Assign Myeloma Response Is Analogous to the IMWG Response Criteria","volume":"59","author":"Fouquet","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/leu.2012.189","article-title":"Suppression of Uninvolved Immunoglobulins Defined by Heavy\/light Chain Pair Suppression Is a Risk Factor for Progression of MGUS","volume":"27","author":"Katzmann","year":"2013","journal-title":"Leukemia"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1007\/s00277-021-04653-2","article-title":"Immunoparesis Defined by Heavy\/light Chain Pair Suppression in Smoldering Multiple Myeloma Shows Initial Isotype Specificity and Involves Other Isotypes in Advanced Disease","volume":"100","author":"Isola","year":"2021","journal-title":"Ann. Hematol."},{"key":"ref_54","first-page":"4293","article-title":"A Novel Biomarker Score for the Screening and Management of Patients with Plasma Cell Proliferative Disorders","volume":"23","author":"Basile","year":"2019","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1373\/jalm.2017.024307","article-title":"Severe Isotype-Matched Immunosuppression (IMI) as a Potential Risk Factor for Progression of MGUS Patients","volume":"2","author":"Pais","year":"2018","journal-title":"J. Appl. Lab. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1080\/10245332.2015.1101969","article-title":"Early Mortality in Multiple Myeloma: Experiences from a Single Institution","volume":"21","author":"Chen","year":"2016","journal-title":"Hematology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"9219","DOI":"10.1200\/JCO.2005.03.2086","article-title":"Early Mortality after Diagnosis of Multiple Myeloma: Analysis of Patients Entered onto the United Kingdom Medical Research Council Trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party","volume":"23","author":"Augustson","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A Clinical Staging System for Multiple Myeloma. Correlation of Measured Myeloma Cell Mass with Presenting Clinical Features, Response to Treatment, and Survival","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"112687","DOI":"10.1016\/j.jim.2019.112687","article-title":"Sentinel Biomarkers in HCV Positive Patients with Mixed Cryoglobulinemia","volume":"476","author":"Basile","year":"2020","journal-title":"J. Immunol. Methods"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/bab.1929","article-title":"Biomarkers of Minimal Residual Disease in Rituximab-Treated Patients with Mixed Cryoglobulinemia","volume":"68","author":"Basile","year":"2021","journal-title":"Biotechnol. Appl. Biochem."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/13\/5\/743\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:24:12Z","timestamp":1760124252000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/13\/5\/743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,27]]},"references-count":60,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["jpm13050743"],"URL":"https:\/\/doi.org\/10.3390\/jpm13050743","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,27]]}}}